Literature DB >> 23802769

Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components.

W Xiao1, C A Tormey, A Capetillo, R W Maitta.   

Abstract

BACKGROUND AND OBJECTIVES: Transfusions of pooled or apheresis platelets are seen as equally effective in increasing platelet counts with similar rates of transfusion reactions. It has been suggested that allergic transfusion reactions (ATRs) to platelets are associated with recipient and donor factors. In this study, we assessed differences in ATR rates among individuals who received platelet components at two academic medical centres.
MATERIALS AND METHODS: A total of 45 189 leukoreduced platelet products were transfused during the study period of which 31 748 were apheresis units and 13 441 were pooled units.
RESULTS: Transfusion reactions were reported in 0·6% (277 of 45 189) of platelet transfusions. The reaction rate was significantly higher in pooled (102 of 13 441) than in apheresis (175 of 31 748) (0·76% vs. 0·55%, respectively, P = 0·01) components. However, an analysis of reactions by categories indicated that only the ATR rate was significantly higher in pooled (55 of 13 441) products as compared with apheresis (76 of 31 748) (0·41% vs. 0·24%, respectively, P = 0·0029) platelets. Moreover, there was no difference in the rate of ABO mismatch between pooled and apheresis products.
CONCLUSION: Our data indicate that pooled platelet components are associated with higher ATR rates than apheresis platelets, suggesting that these components may not be completely equivalent from the standpoint of adverse events. Further investigation is needed to address whether differences in ATRs are related to the pooling process or the extent of donor antigen exposure.
© 2013 International Society of Blood Transfusion.

Entities:  

Keywords:  allergic reactions; platelets; pooled platelets; single-donor platelets; transfusion

Mesh:

Year:  2013        PMID: 23802769     DOI: 10.1111/vox.12063

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  6 in total

1.  Transfusion-related adverse events in the Platelet Dose study.

Authors:  Richard M Kaufman; Susan F Assmann; Darrell J Triulzi; Ronald G Strauss; Paul Ness; Suzanne Granger; Sherrill J Slichter
Journal:  Transfusion       Date:  2014-07-28       Impact factor: 3.157

2.  What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Meghan Delaney; Oliver Karam; Lani Lieberman; Katherine Steffen; Jennifer A Muszynski; Ruchika Goel; Scot T Bateman; Robert I Parker; Marianne E Nellis; Kenneth E Remy
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

3.  Transfusion and component characteristics are not associated with allergic transfusion reactions to apheresis platelets.

Authors:  William J Savage; Aaron A R Tobian; Jessica H Savage; Robert G Hamilton; P Dayand Borge; Richard M Kaufman; Paul M Ness
Journal:  Transfusion       Date:  2014-09-10       Impact factor: 3.157

4.  Transfusion-associated adverse reactions (TAARs) and cytokine accumulations in the stored blood components: the impact of prestorage versus poststorage leukoreduction.

Authors:  Chih-Chun Chang; Tai-Chen Lee; Ming-Jang Su; Hsiu-Chen Lin; Fang-Yi Cheng; Yi-Ting Chen; Tzung-Hai Yen; Fang-Yeh Chu
Journal:  Oncotarget       Date:  2017-12-07

5.  Perioperative Single-Donor Platelet Apheresis and Red Blood Cell Transfusion Impact on 90-Day and Overall Survival in Living Donor Liver Transplantation.

Authors:  Wei Zheng; Kang-Mei Zhao; Li-Hui Luo; Yang Yu; Sheng-Mei Zhu
Journal:  Chin Med J (Engl)       Date:  2018-02-20       Impact factor: 2.628

Review 6.  Platelet Transfusion: And Update on Challenges and Outcomes.

Authors:  Pilar Solves Alcaina
Journal:  J Blood Med       Date:  2020-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.